These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

326 related items for PubMed ID: 25332243

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alpha-2B in patients with metastatic melanoma.
    McDermott DF, Mier JW, Lawrence DP, van den Brink MR, Clancy MA, Rubin KM, Atkins MB.
    Clin Cancer Res; 2000 Jun; 6(6):2201-8. PubMed ID: 10873069
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial.
    Eton O, Legha SS, Bedikian AY, Lee JJ, Buzaid AC, Hodges C, Ring SE, Papadopoulos NE, Plager C, East MJ, Zhan F, Benjamin RS.
    J Clin Oncol; 2002 Apr 15; 20(8):2045-52. PubMed ID: 11956264
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony-stimulating factor, and tamoxifen for patients with metastatic melanoma.
    O'Day SJ, Gammon G, Boasberg PD, Martin MA, Kristedja TS, Guo M, Stern S, Edwards S, Fournier P, Weisberg M, Cannon M, Fawzy NW, Johnson TD, Essner R, Foshag LJ, Morton DL.
    J Clin Oncol; 1999 Sep 15; 17(9):2752-61. PubMed ID: 10561350
    [Abstract] [Full Text] [Related]

  • 12. Biochemotherapy in the treatment of metastatic melanoma in selected patients.
    González Astorga B, Jiménez Rubiano B, Delgado Pérez JR, Valdivia Bautista J, Sánchez Toro C, González Flores E, Luque Caro R, Castellón Rubio V.
    Clin Transl Oncol; 2009 Jun 15; 11(6):382-6. PubMed ID: 19531453
    [Abstract] [Full Text] [Related]

  • 13. High frequency of brain metastases after adjuvant therapy for high-risk melanoma.
    Samlowski WE, Moon J, Witter M, Atkins MB, Kirkwood JM, Othus M, Ribas A, Sondak VK, Flaherty LE.
    Cancer Med; 2017 Nov 15; 6(11):2576-2585. PubMed ID: 28994212
    [Abstract] [Full Text] [Related]

  • 14. Rationale for intergroup trial E-3695 comparing concurrent biochemotherapy with cisplatin, vinblastine, and DTIC alone in patients with metastatic melanoma.
    Flaherty LE.
    Cancer J Sci Am; 2000 Feb 15; 6 Suppl 1():S15-20. PubMed ID: 10685653
    [Abstract] [Full Text] [Related]

  • 15. A phase II study of biochemotherapy for the treatment of metastatic malignant melanoma.
    Gibbs P, Iannucci A, Becker M, Allen J, O'Driscoll M, McDowell K, Williams P, Rosse P, Murphy J, Gonzalez R.
    Melanoma Res; 2000 Apr 15; 10(2):171-9. PubMed ID: 10803718
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG).
    Hauschild A, Garbe C, Stolz W, Ellwanger U, Seiter S, Dummer R, Ugurel S, Sebastian G, Nashan D, Linse R, Achtelik W, Mohr P, Kaufmann R, Fey M, Ulrich J, Tilgen W.
    Br J Cancer; 2001 Apr 20; 84(8):1036-42. PubMed ID: 11308250
    [Abstract] [Full Text] [Related]

  • 20. Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-alpha2b in metastatic melanoma.
    Bajetta E, Del Vecchio M, Nova P, Fusi A, Daponte A, Sertoli MR, Queirolo P, Taveggia P, Bernengo MG, Legha SS, Formisano B, Cascinelli N.
    Ann Oncol; 2006 Apr 20; 17(4):571-7. PubMed ID: 16469753
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.